Page last updated: 2024-11-07

aldophosphamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aldophosphamide: metabolite of cyclophosphamide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107744
CHEMBL ID1593
CHEBI ID2560
SCHEMBL ID9972854
MeSH IDM0049031

Synonyms (19)

Synonym
aldophosphamide
35144-64-0
C07645
CHEMBL1593 ,
chebi:2560 ,
3-oxopropyl n,n-bis(2-chloroethyl)phosphorodiamidate
3-[amino-[bis(2-chloroethyl)amino]phosphoryl]oxypropanal
AC1Q6SYU ,
unii-7am2ilm9fi
7am2ilm9fi ,
phosphorodiamidic acid, n,n-bis(2-chloroethyl)-, 3-oxopropyl ester
SCHEMBL9972854
3-((amino(bis(2-chloroethyl)amino)phosphinyl)oxy)propanal
AKOS027322741
Q15711205
DTXSID60956594
3-oxopropyln,n-bis(2-chloroethyl)phosphorodiamidate
CS-0064648
HY-114917

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It is shown that not acrolein, but OHCP itself is the true toxic metabolite of cyclophosphamide."( Causes and possibilities to circumvent cyclophosphamide toxicity.
Voelcker, G, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" The results are consistent with those obtained for cancer patients, in spite of a wide interpatient variability of concentrations and pharmacokinetic parameters."( Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.
Belfayol-Pisanté, L; Fauvelle, F; Guillevin, L; Tod, M,
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrogen mustardCompounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Cyclophosphamide Action Pathway922
Cyclophosphamide Metabolism Pathway922
Cyclophosphamide Pathway, Pharmacokinetics73

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (32.43)18.7374
1990's16 (43.24)18.2507
2000's6 (16.22)29.6817
2010's2 (5.41)24.3611
2020's1 (2.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.84 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.13%)5.53%
Reviews1 (2.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]